Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cardiol Therapeutics Inc. (T:CRDL)

Business Focus: Pharmaceuticals

Log in or join to add this stock to your watch list.
Jul 25, 2019 09:53 am ET
Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
Oakville, Ontario--(Newsfile Corp. - July 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), focused on producing pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure, announces today that David Elsley, President and CEO of Cardiol, will be presenting at the Canaccord Genuity 39th Annual Growth Conference being held August 7-8, 2019 at the InterContinental Boston, MA. For two highly productive days, some of the best of the global growth universe will come together at the conference to share knowledge, discuss emerging trends, build relationships, identify opportunities, and ignite global ideas for growth. Cardiol's presentation is scheduled for August 8th at 11:30 a.m. EDT. The Company's management is also available for one-on-one meetings.
Jul 03, 2019 08:35 am ET
Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Jul 03, 2019 08:35 am ET
Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing
NEW YORK, July 3, 2019 /PRNewswire/ -- Virtual Investor Conferences, in partnership with Grit Capital, today announced that the presentations from our recent virtual event are now available for on-demand viewing. Eight public & private company executives provided insight on innovation, consolidation, international expansion and specialization in millennial investment industries. Login to now to watch the presentations and hear answers to questions from the audience....
Jun 21, 2019 12:50 pm ET
Grit Capital's Live-Stream Virtual Investor Conference June 26th
9 Company Executives of small cap millennial themed companies share their vision and answer questions live at VirtualInvestorConferences.com
Jun 20, 2019 09:06 am ET
Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation
Oakville, Ontario--(Newsfile Corp. - June 20, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation.
Jun 13, 2019 04:39 pm ET
Cardiol Therapeutics Reports Results of its AGM
Oakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for heart disease, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, on June 12, 2019. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.
Jun 10, 2019 11:03 am ET
Cardiol Therapeutics to Webcast Annual General Meeting on June 12
Oakville, Ontario--(Newsfile Corp. - June 10, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it will be webcasting the informal portion of its annual general meeting (AGM) being held at Vantage Venues, 150 King Street West, 27th Floor, Toronto, on June 12, 2019, at 9:00 a.m. EDT.
Jun 06, 2019 08:35 am ET
Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations
Jun 03, 2019 08:03 am ET
May 31, 2019 08:35 am ET
Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th
Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com
May 30, 2019 08:33 am ET
Cardiol Therapeutics Commences Trading on the OTCQX
Oakville, Ontario--(Newsfile Corp. - May 30, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it has qualified to trade on the OTCQX® Best Market and begins trading today under the symbol "CRTPF". U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
May 07, 2019 09:00 am ET
Cardiol Therapeutics at the Intersection of Pharmaceutical CBD and Biotech, Plus Exclusive CEO Interview -- CFN Media
Seattle, Washington--(Newsfile Corp. - May 7, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article and exclusive CEO video interview covering Cardiol Therapeutics Inc. (Cardiol) (TSX: CRDL) (OTC Pink: CRTPF), its development of cannabidiol (CBD) based drugs, and its plan to launch a commercial pharmaceutical CBD oil product.
Mar 28, 2019 08:47 am ET
Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - March 28, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and development of pharmaceutical cannabidiol and targeted therapies for inflammatory disease, today announced the filing of its audited year-end financial statements and management's discussion and analysis for the year ended December 31, 2018. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.
Mar 21, 2019 01:26 pm ET
The Science Behind Medical Marijuana is Flawed -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article discussing Cardiol Therapeutics (TSX: CRDL), a Canadian...
Mar 06, 2019 08:37 am ET
Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer
Oakville, Ontario--(Newsfile Corp. - March 6, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, is pleased to announce the appointment of Thomas (Tom) Moffatt, BBA, as Chief Commercial Officer.
Feb 20, 2019 09:00 am ET
Heart Failure and CBD -- CFN Media
via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Cardiol Therapeutics (TSX: CRDL) (OTC: CRTPF) and its...
Jan 30, 2019 09:00 am ET
Cardiol Therapeutics Introducing Major Supply of Pharmaceutical CBD to Meet Supply Crunch -- CFN Media
Seattle, Washington--(Newsfile Corp. - January 30, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Cardiol Therapeutics' (TSX: CRDL) upcoming launch of its pharmaceutical CBD products, with the capacity to scale manufacturing to metric tonnes per year.
Jan 28, 2019 12:30 pm ET
Cardiol Therapeutics Inc. Closes the Market
TORONTO, Jan. 25, 2019 /CNW/ - David Elsley, President & CEO, Cardiol Therapeutics Inc. (CRDL), joined Loui Anastasopoulos, President, Capital Formation, Toronto Stock Exchange & TSX Venture Exchange, to close the market. Cardiol Therapeutics is a biotechnology company specializing in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. Cardiol Therapeutics Inc. commenced trading on Toronto Stock Exchange on December 20, 2018.
Jan 18, 2019 09:14 am ET
Cardiol Therapeutics Inc. Closes Over-Allotment
Oakville, Ontario--(Newsfile Corp. - January 18, 2019) -  Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announced today that the underwriters for the Company's initial public offering (the "Offering") have exercised their over-allotment option (the "Over-Allotment Option") to purchase an additional 374,544 Class A common shares of Cardiol (the "Optional Shares") at a price of $4.62 per Optional Share. The sale of the Optional Shares increases the gross proceeds of the Offering by $1,730,393, resulting in aggregate gross proceeds to Cardiol of $16,872,720.
Dec 20, 2018 09:27 am ET
Cardiol Therapeutics Completes Initial Public Offering and the Company's Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols "CRDL" and "CRDL.WT"
Oakville, Ontario--(Newsfile Corp. - December 20, 2018) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer, announces that it has completed its initial public offering (the "IPO") on the Toronto Stock Exchange (the "TSX"). In connection with the IPO, Cardiol issued (a) 3,000,000 units (the "Units") at a price of $5.00 per Unit, with each Unit consisting of one Class A common share of the Company (a "Unit Share" and each Class A common share, a "Common Share") and one Common Share purchase warrant of the Company (a "Warrant"); and (b) an additional 374,544 Warrants at a price of $0.38 per Warrant pursuant to the partial exercise by the underwriters of the Over-Allotment Option, resulting in aggregate gross proceeds of $15,142,327. Cardiol's Common Shares will commence trading today on the TSX under the symbol "CRDL" and the Warrants will commence trading today under the symbol "CRDL.WT".
Dec 20, 2018 08:45 am ET
IIROC Trade Resumption - CRDL
TORONTO, Dec. 20, 2018 /CNW/ - Trading resumes in:
Dec 20, 2018 07:14 am ET
IIROC Trading Halt - CRDL
TORONTO, Dec. 20, 2018 /CNW/ - The following issues have been halted by IIROC: